2017
Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.
Wright N, Rida P, Krishnamurti U, Li X, Aneja R. Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity. Frontiers In Bioscience-Landmark 2017, 22: 193-211. PMID: 27814611, DOI: 10.2741/4481.Peer-Reviewed Original ResearchConceptsEthnic disparitiesAfrican AmericansAggressive breast cancer subtypeUnique tumor biologyBreast cancer subtypesPrecision medicine toolsDiagnostic assaysIndividualized cancer treatmentRacial health disparitiesClinical outcomesDevelopment of drugsPatient populationAncestry-associated differencesEfficacy biomarkersTargeted drugsHigh recurrenceMortality rateCentrosomal aberrationsBreast tumorsTumor biologyCancer subtypesHealth disparitiesMedicine toolsCancer treatmentPersonalized oncology
2013
The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions
Deftereos G, Finkelstein S, Jackson S, Ellsworth E, Krishnamurti U, Liu Y, Silverman J, Binkert C, Ujevich B, Mohanty A. The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions. Modern Pathology 2013, 27: 594-601. PMID: 24051700, DOI: 10.1038/modpathol.2013.147.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorBiopsy, Fine-NeedleCentrifugationDNA Mutational AnalysisDNA, NeoplasmGenetic Predisposition to DiseaseHumansLoss of HeterozygosityMicrodissectionMutationPancreatic NeoplasmsPolymerase Chain ReactionPredictive Value of TestsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsConceptsFine-needle aspirationPancreatic solid massesDiagnostic yieldSupernatant fluidTumor DNASolid massHigh clinical suspicionDetectable mutationsSolid mass lesionQuantitative PCRClinical suspicionAtypical cellsDefinitive diagnosisMass lesionCytology smearsFluid specimensFNA smearsMolecular analysisAdjunct methodAdequate DNAMutational profilingCell blocksCytocentrifugation supernatant fluidSmearsBroad panel
2007
Analysis of loss of heterozygosity in atypical and negative bile duct brushing cytology specimens with malignant outcome: are "false-negative" cytologic findings a representation of morphologically subtle molecular alterations?
Krishnamurti U, Sasatomi E, Swalsky P, Finkelstein S, Ohori N. Analysis of loss of heterozygosity in atypical and negative bile duct brushing cytology specimens with malignant outcome: are "false-negative" cytologic findings a representation of morphologically subtle molecular alterations? Archives Of Pathology & Laboratory Medicine 2007, 131: 74-80. PMID: 17227126, DOI: 10.5858/2007-131-74-aolohi.Peer-Reviewed Original ResearchConceptsK-ras mutationsBile duct brushingsLoss of heterozygosityMalignant outcomeFractional allelic lossDuct brushingsCytology casesAllelic lossMolecular alterationsBile duct brushing cytologyPilot studyConventional cytologic evaluationSurgical pathology specimenCorresponding surgical specimensDuct brushing cytologySurgical pathology specimensDetection of malignancySubtle molecular alterationsSurgical outcomesSurgical specimenPathology specimenCytologic findingsSurgical specimensBrushing cytologyCytologic evaluation
2005
Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
Krishnamurti U, Sasatomi E, Swalsky P, Jones M, Finkelstein S. Microdissection-based mutational genotyping of serous borderline tumors of the ovary. International Journal Of Gynecological Pathology 2005, 24: 56-61. PMID: 15626917.Peer-Reviewed Original Research